Anticandidal Agents provides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules.
Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines.
Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics.
Awanish Kumar is a Professor in the Bio Technology Faculty at the National Insitute of Technology Raipur, India. He has previously held posts at the National Institute of Pharma Education & Research; McGill University, Canada; and Jawaharlal Nehru University in New Dehli. His key interests in research are the development of drug targeting methods in therapeutic treatments.
Chapter 1. Introduction Chapter 2. Host-Pathogen Interaction Chapter 3. Antifungals Used Against Candidiasis Chapter 4. Drug Resistance in Candida Chapter 5. Multidrug Resistance and Transporters Chapter 6. Potential Anticandidal Targets Chapter 7. Drug Development Strategies Chapter 8. Conclusion